Zile, Michael R.

Angiotensin-neprilysin inhibition versus enalapril in heart failure

McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine

Heart Failure Treatment and ManagementRenin-Angiotensin System Studies

Cited by 6,957

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine

Heart Failure Treatment and ManagementRenin-Angiotensin System Studies

Cited by 2,430

Irbesartan in patients with heart failure and preserved ejection fraction

Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,960

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,009

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap

Shah, S. J., Kitzman, D. W., Borlaug, B. A., van Heerebeek, L., Zile, M. R., Kass, D. A., & Paulus, W. J. (2016) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,003

Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin

Zile, M. R., Baicu, C. F., S. Ikonomidis, J., Stroud, R. E., Nietert, P. J., Bradshaw, A. D., Slater, R., Palmer, B. M., Van Buren, P., Meyer, M., et al. (2015) · Circulation

Cardiovascular Function and Risk FactorsCardiac Fibrosis and Remodeling

Cited by 681

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

Packer, M., McMurray, J. J. V., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2015) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 673

Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial

Ahmed, A., Rich, M. W., Fleg, J. L., Zile, M. R., Young, J. B., Kitzman, D. W., Love, T. E., Aronow, W. S., Adams, K. F., & Gheorghiade, M. (2006) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 605

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

Solomon, S. D., Vaduganathan, M., L. Claggett, B., Packer, M., Zile, M., Swedberg, K., Rouleau, J., A. Pfeffer, M., Desai, A., H. Lund, L., et al. (2020) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 551

Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction

Zile, M. R., Gottdiener, J. S., Hetzel, S. J., McMurray, J. J., Komajda, M., McKelvie, R., Baicu, C. F., Massie, B. M., & Carson, P. E. (2011) · Circulation

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 517

Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial

Haass, M., Kitzman, D. W., Anand, I. S., Miller, A., Zile, M. R., Massie, B. M., & Carson, P. E. (2011) · Circulation: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 366

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial

Kristensen, S. L., Preiss, D., Jhund, P. S., Squire, I., Cardoso, J. S., Merkely, B., Martinez, F., Starling, R. C., Desai, A. S., Lefkowitz, M. P., et al. (2016) · Circulation Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 359

Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)

Kristensen, S. L., Mogensen, U. M., Jhund, P. S., Petrie, M. C., Preiss, D., Win, S., Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., et al. (2017) · Circulation

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 202

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure

Kramer, C. M., Borlaug, B. A., Zile, M. R., Ruff, D., DiMaria, J. M., Menon, V., Ou, Y., Zarante, A. M., Hurt, K. C., Murakami, M., et al. (2025) · Journal of the American College of Cardiology

Cardiovascular Disease and AdiposityHeart Failure Treatment and Management

Cited by 200

Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)

Okumura, N., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., Zile, M. R., Solomon, S. D., et al. (2016) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 186

A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS

Domanski, M. J., Krause-Steinrauf, H., Massie, B. M., Deedwania, P., Follmann, D., Kovar, D., Murray, D., Oren, R., Rosenberg, Y., Young, J., et al. (2003) · Journal of Cardiac Failure

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 176

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

Borlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M. (2025) · Nature Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 166

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

Jackson, A. M., Jhund, P. S., Anand, I. S., Düngen, H.-D., Lam, C. S. P., Lefkowitz, M. P., Linssen, G., Lund, L. H., Maggioni, A. P., Pfeffer, M. A., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 156

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Zile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., et al. (2025) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 74

Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Packer, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 49

Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction

Docherty, K. F., Shen, L., Castagno, D., Petrie, M. C., Abraham, W. T., Böhm, M., Desai, A. S., Dickstein, K., Køber, L. V., Packer, M., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 42

Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate

Lam, P. H., Gupta, N., Dooley, D. J., Singh, S., Deedwania, P., Zile, M. R., Bhatt, D. L., Morgan, C. J., Pitt, B., Fonarow, G. C., et al. (2018) · The American Journal of Medicine

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 36

Health‐related quality of life outcomes in PARAGON‐HF

Chandra, A., Polanczyk, C. A., Claggett, B. L., Vaduganathan, M., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Schwende, H., et al. (2022) · European Journal of Heart Failure

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 33

Myocardial Infarction in Heart Failure With Preserved Ejection Fraction

Cunningham, J. W., Vaduganathan, M., Claggett, B. L., John, J. E., Desai, A. S., Lewis, E. F., Zile, M. R., Carson, P., Jhund, P. S., Kober, L., et al. (2020) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 33